Bruker has announced the planned discontinuation of the IsoSpark and IsoLight platforms. Customers with questions about transition options and last-time-buy opportunities should contact their Bruker sales representative.
In this Webinar we discuss:
Evaluate T cell responses induced by various bispecific T cell engagers across phenotypes
Understand the heterogeneity of TIL polyfunctionality in solid tumors in response to checkpoint inhibitors
Uniquely correlate clinical anti-tumor responses with IsoPlexis data
Optimize combination cancer vaccines in melanoma using model systems
